{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:38:30Z","timestamp":1791315510402,"version":"4.3.1"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"18","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,6,20]]},"abstract":"<jats:p> Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. <\/jats:p><jats:p> In the longest follow-up, to our knowledge, for a KRAS<jats:sup>G12C<\/jats:sup> inhibitor, we assessed the long-term efficacy, safety, and biomarkers of sotorasib in patients with KRAS G12C-mutated advanced non\u2013small-cell lung cancer (NSCLC) from the CodeBreaK 100 clinical trial (ClinicalTrials.gov identifier: NCT03600883 ). This multicenter, single-group, open-label phase I\/phase II trial enrolled 174 patients with KRAS G12C-mutated, locally advanced or metastatic NSCLC after progression on prior therapies. Patients (N = 174) received sotorasib 960 mg once daily with the primary end points for phase I of safety and tolerability and for phase II of objective response rate (ORR). Sotorasib produced an ORR of 41%, median duration of response of 12.3 months, progression-free survival (PFS) of 6.3 months, overall survival (OS) of 12.5 months, and 2-year OS rate of 33%. Long-term clinical benefit (PFS \u2265 12 months) was observed in 40 (23%) patients across PD-L1 expression levels, in a proportion of patients with somatic STK11 and\/or KEAP1 alterations, and was associated with lower baseline circulating tumor DNA levels. Sotorasib was well tolerated, with few late-onset treatment-related toxicities, none of which led to treatment discontinuation. These results demonstrate the long-term benefit of sotorasib, including in subgroups with poor prognosis. <\/jats:p>","DOI":"10.1200\/jco.22.02524","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T20:00:41Z","timestamp":1682452841000},"page":"3311-3317","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":167,"title":["Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS<\/i> G12C-Mutated Non\u2013Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03600883","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5061-0072","authenticated-orcid":false,"given":"Grace K.","family":"Dy","sequence":"first","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-9612","authenticated-orcid":false,"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsidhar","family":"Velcheti","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, New York University Langone, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-2191","authenticated-orcid":false,"given":"Gerald S.","family":"Falchook","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute at HealthONE, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-5351","authenticated-orcid":false,"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"name":"Institut Bergonie, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-8812","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[{"name":"Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"Sacher","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-2505","authenticated-orcid":false,"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Shizuoka Cancer Center, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":false,"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Dooms","sequence":"additional","affiliation":[{"name":"University Hospitals KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-7132","authenticated-orcid":false,"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0988-0828","authenticated-orcid":false,"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[{"name":"Hopitaux Universitaires de Geneve, Geneve, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-9344","authenticated-orcid":false,"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":false,"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[{"name":"West German Cancer Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[{"name":"Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, APHM, INSERM, NCRS, CRCM, H\u00f4pital de la Timone, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2196-3503","authenticated-orcid":false,"given":"Piro","family":"Lito","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-964X","authenticated-orcid":false,"given":"Qui","family":"Tran","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-622X","authenticated-orcid":false,"given":"Abraham","family":"Anderson","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antreas","family":"Hindoyan","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Snyder","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinandos","family":"Skoulidis","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6661-8733","authenticated-orcid":false,"given":"Bob T.","family":"Li","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70586-2"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1694-1"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad6204"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1884-x"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1038\/nature12796"},{"key":"b11","volume-title":"LUMYKRAS (Sotorasib). Summary of Product Characteristics","year":"2021"},{"key":"b12","volume-title":"LUMYKRAS (Sotorasib). Summary of Product Characteristics","author":"Amgen Europe BV","year":"2022"},{"key":"b13","volume-title":"LUMAKRAS\u00ae (Sotorasib) Receives Approval in Japan for Patients With KRAS G12C-Mutated Advanced Non-small Cell Lung Cancer","author":"BioSpace","year":"2022"},{"key":"b14","volume-title":"LUMAKRAS (Sotorasib) Tablets, for Oral Use. Prescribing Information","year":"2021"},{"key":"b15","volume-title":"A Phase 1\/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","author":"ClinicalTrials.gov","year":"2022"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204619"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60845-X"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.3438"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1985"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.05.005"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.016"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00221-0"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc4308"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0652-7"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02047-z"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003027"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.013"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04065-2"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01775-6"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.22.02524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T22:02:05Z","timestamp":1686780125000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.02524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,6,20]]}},"alternative-id":["10.1200\/JCO.22.02524"],"URL":"https:\/\/doi.org\/10.1200\/jco.22.02524","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"2022-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}